PHIL in the Treatment of Intracranial dAVF. (PHIL dAVF)
Diseases of the Cardiovascular System
What is the purpose of this trial?
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
- Ages22 years - 80 years
- Trial withMicrovention-Terumo, Inc.
- Start Date05/03/2019
- End Date05/31/2019
- Last Updated11/11/2022
- Study HIC#2000023267